Results 221 to 230 of about 33,100 (295)

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells. [PDF]

Chemistry
Elias MG, Khoury A, Fatima S, Mann TJ, Karan S, Mikhael M, de Souza P, Gordon CP, Scott KF, Aldrich-Wright JR.   +9 more
europepmc   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Exploiting vitamin C as a prooxidant to activate ROS-responsive prodrugs for potent and selective tumor killing. [PDF]

Redox Biol
Ali T, Ponnamperumage TNF, Miller CJ, Li D, Awoyera WO, Peterson AK, Gao H, Pandey J, Jakusz JAR, Fan H, Koelsch GE, Arnold LA, Jorns JM, Cheng YC, Roy A, Zhou G, Peng X.   +16 more
europepmc   +1 more source

Plasma EC90 multiples are drug, target site and species specific—A physiologically based pharmacokinetic modelling example of nirmatrelvir central nervous system distribution

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Achieving minimum unbound drug concentration in plasma above in vitro EC90 is a common antiviral pharmacokinetic/pharmacodynamic (PK/PD) target. However, it often overlooks restricted distribution into target sites like the central nervous system (CNS), where a trough concentration above 1 × EC90 is needed.
Daan W. van Valkengoed, Xuanlin Liu, Sean N. Avedissian, Courtney V. Fletcher, Ashley N. Brown, Elizabeth C. M. de Lange, Anne‐Grete Märtson   +6 more
wiley   +1 more source

Nanobody-Conjugated Theranostic Prodrug Targeting α_vβ₃ Integrin Enables Precision Cancer Therapy With Real-Time Imaging. [PDF]

Adv Healthc Mater
Karan S, Lee H, Naskar R, Cho MY, Park HS, Han EH, Hore S, Cho SH, Lam TNK, Son T, Park TJ, Hwang I, Sessler JL, Hong KS.   +13 more
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Precision Oncology via Radiotherapy-Triggered Drug Delivery: Mechanisms, Molecular Engineering, and Clinical Translation. [PDF]

Adv Sci (Weinh)
Jiang J, Zhang T, Dong J, Sun W.
europepmc   +1 more source

Bioactivation and Metabolism of Amino Acid MDMA Prodrugs in Zebrafish Embryos, Human Liver S9, Whole Blood, and Microdosed Human Urine. [PDF]

Drug Test Anal
Wellenberg SK, Wagmann L, Kroesen MD, Schippers P, Grill M, Herrmann J, Meyer MR.   +6 more
europepmc   +1 more source

On the Edge of Benefit and Harm: Reactive Oxygen Species in Cancer. [PDF]

Int J Mol Sci
Nikiforova AB.
europepmc   +1 more source